EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours

Rachel N Grisham, Elizabeth Hopp, Kathryn Pennington, Robert Holloway, Robert M Wenham, Pawel Blecharz, Lauren Dockery, Koji Matsuo, Ritu Salani, Mariusz Bidzinski, Patricia Braly, Paul Celano und 9 weitere

Clinical and Translational Medicine · 2026-01 · 16 (1)

DOI: 10.1002/ctm2.70568 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Medicine, online erschienen am 10.01.2026. Verfasst von Rachel N Grisham und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Granulosa Cell Tumor, Neoplasm Recurrence, Local, Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, SpringWorks Therapeutics, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adult ovarian granulosa cell tumours (GCT) are the most common subtype of ovarian sex cord‐stromal tumours. Forkhead transcription factor FOXL2 is required for development and function of normal granulosa cells, including proliferation and ovarian hormone synthesis. A single somatic missense mutation in FOXL2 , c.402C > G (p.Cys134Trp), has previously been identified in the majority of GCT and is a pathognomonic marker for this tumour type. NOTCH activation contributes to GCT survival in preclinical models, and NOTCH2 and NOTCH3 are critical for embryonic development of the ovary and function of the ovarian follicle. Nirogacestat is a potent, selective, noncompetitive inhibitor of gamma secretase, which inhibits NOTCH pathway signalling. Treatment of GCT with nirogacestat was predicted to inhibit granulosa cell survival.

Methods

A Phase II clinical trial was conducted to assess antitumour activity of nirogacestat in adult patients with relapsed/refractory ovarian GCT (NCT05348356). This study enrolled 53 patients; all were evaluable for efficacy and safety. Endpoints included objective response rate by Response Evaluation Criteria in Solid Tumors v1.1 and 6‐month progression‐free survival (PFS6). Fresh or archival tumour samples were analysed for mutational profiling.

Results

Patients received a median of 5 prior lines of therapy (range, 1–13) and a median of 3.7 months of treatment (range, 0–20 months). A decrease in tumour burden was seen in 16 (30%) patients; however, there were no confirmed objective responses. Thirty‐one (58%) patients had stable disease; 18 (34%) had progressive disease. Eleven (21%) patients achieved PFS6. No correlations with disease stability were found with baseline clinical characteristics. All 3 patients who had an activating NOTCH1 mutation achieved PFS6.

Conclusions

In patients with heavily pretreated GCT, nirogacestat treatment resulted in durable disease stabilisation of at least 7 weeks for 58% of patients, with 21% achieving PFS6, including the 3 patients whose tumours had an activating NOTCH1 mutation. Key points This Phase II clinical trial of a rare tumour achieved its enrolment target in under 1 year and completed primary analysis within 2 years. 87% (46 of 53 patients who received nirogacestat) had fresh or archival biopsies that were analysed by next‐generation sequencing for mutational profiling. Of the 3 patients with activating NOTCH1 mutations, all achieved 6‐month progression‐free survival (PFS6); 8 other patients also achieved PFS6 but did not share a common mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulosa Cell TumorNeoplasm Recurrence, LocalOvarian NeoplasmsAdultAgedFemaleHumansMiddle Aged

Stichwörter der Autor:innen

NOTCHgamma secretase inhibitorsmutational profilingtumour recurrence

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Obstetrics and Gynecology, Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Gynecologic Oncology, University of Washington Medical Center, Seattle, Washington, USA.
  • Gynecologic Oncology Program, AdventHealth Medical Group GYN Oncology at Orlando, Orlando, Florida, USA.
  • Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.

Förderung

  • NCI NIH HHS
  • SpringWorks Therapeutics, Inc

Zitieren

APA

Grisham, R. N., Hopp, E., Pennington, K., Holloway, R., Wenham, R. M., Blecharz, P., Dockery, L., Matsuo, K., Salani, R., Bidzinski, M., Braly, P., Celano, P., Reid, T., Seward, S., Lewis, J., Johnson, M., DuBose, R., Ahn, S., Cheng, S., …, & Konstantinopoulos, P. A. (2026). Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours. Clinical and Translational Medicine, 16(1). https://doi.org/10.1002/ctm2.70568

Vancouver

Grisham RN, Hopp E, Pennington K, Holloway R, Wenham RM, Blecharz P, et al. Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours. Clinical and Translational Medicine. 2026;16(1). doi:10.1002/ctm2.70568

BibTeX
@article{Grisham2026,
  author = {Grisham, Rachel N and Hopp, Elizabeth and Pennington, Kathryn and Holloway, Robert and Wenham, Robert M and Blecharz, Pawel and Dockery, Lauren and Matsuo, Koji and Salani, Ritu and Bidzinski, Mariusz and Braly, Patricia and Celano, Paul and Reid, Thomas and Seward, Shelly and Lewis, Jocelyn and Johnson, Mark and DuBose, Robert and Ahn, Sarah and Cheng, Shinta and Alvero, Carmelita and Konstantinopoulos, Panagiotis A},
  title = {Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {1},
  doi = {10.1002/ctm2.70568}
}
Kostenlos starten →